ScholarLens Back to search
2019•Kidney International ReportsOpen access

Abatacept in Steroid-Dependent Minimal Change Disease and CD80-uria

Robert T. Isom, Stanford Shoor, John Higgins, Gabriel Cara‐Fuentes, Richard J. Johnson

Open full text 14 citations

Abstract

Recently there has been interest in the role of CTLA-4 Ig therapy for nephrotic syndrome due to minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).1,2 Although the effects of CTLA-4 Ig for FSGS have been mixed,1–3 there is very limited information on the effect of CTLA-4 Ig (abatacept) in MCD.1,4 There has been one report of a child with relapsing MCD and high levels of urinary CD80 (also known as B7.1) in which administration of abatacept resulted in rapid remission but subsequent relapse.

Open-access reader

About this research paper

What this paper is about

Recently there has been interest in the role of CTLA-4 Ig therapy for nephrotic syndrome due to minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).1,2 Although the effects of CTLA-4 Ig for FSGS have been mixed,1–3 there is very limited information on the effect of CTLA-4 Ig (abatacept) in MCD.1,4 There has been one report of a child with relapsing MCD and high levels of urinary CD80 (also known as B7.1) in which administration of abatacept resulted in rapid remission but subsequent relapse.

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Recently there has been interest in the role of CTLA-4 Ig therapy for nephrotic syndrome due to minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).1,2 Although the effects of CTLA-4 Ig for FSGS have been mixed,1–3 there is very limited information on the effect of CTLA-4 Ig (abatacept) in MCD.1,4 There has been one report of a child with relapsing MCD and high levels of urinary CD80 (also known as B7.1) in which administration of abatacept resulted in rapid remission but subsequent relapse.

Key concepts: Abatacept, Medicine, Minimal change disease, Focal segmental glomerulosclerosis, Nephrotic syndrome, Internal medicine, Immunology, Glomerulonephritis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Abatacept in Steroid-Dependent Minimal Change Disease and CD80-uria — Research Paper | ScholarLens